Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
ACTOPLUS MET is a fixed-dose combination tablet containing pioglitazone (a thiazolidinedione) and metformin hydrochloride, approved in 2005 for type 2 diabetes management. It works by improving insulin sensitivity and reducing hepatic glucose production to lower blood glucose levels. The drug is indicated for patients inadequately controlled on metformin or pioglitazone monotherapy.
Product is in late-stage lifecycle with minimal commercial activity, suggesting limited team expansion and focus shifting toward transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Long-term Use of Sonias Combination Tablets in Patients With Type 2 Diabetes Mellitus
Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone
Special Drug Use Surveillance of Pioglitazone/Metformin Hydrochloride Combination Tablets Survey on Long-term Use for Type 2 Diabetes Mellitus
HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)
Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Insulin Products / Long-term Treatment"
Worked on ACTOPLUS MET at Takeda? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
Working on ACTOPLUS MET offers limited career growth potential given the product's LOE trajectory and minimal linked job opportunities in the current market. Professionals considering roles on this product should expect focus on defensive strategies, generic transition planning, and cost management rather than innovation or market expansion.